June 24, 2026 01:46 PM GMT Viking Therapeutics Inc | North America Ph1 Trial of VK3019 (Amylin Agonist) Initiated; VK2735 Maintenance Data On Track For 3Q26 Key Takeaways VK3019 expands Viking's obesity pipeline. Earlier today, Viking announced the initiation of a Ph1 single ascending dose (SAD) trial for VK3019, its investigational dual amylin and calcitonin receptor agonist (DACRA) being developed for obesity treatment, following FDA clearance of its IND application (press release). The randomized, double ...